Citigroup downgrades Sabra Health Care REIT to Neutral

0 min read     Updated on 23 Jun 2026, 10:24 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Citigroup analyst Nick Joseph downgraded Sabra Health Care REIT from Buy to Neutral and lowered the price target to $19 from $24.

powered bylight_fuzz_icon
43779255

*this image is generated using AI for illustrative purposes only.

Citigroup analyst Nick Joseph has downgraded Sabra Health Care REIT from Buy to Neutral, citing a revised outlook. The firm also lowered its price target for the stock to $19 from the previous $24.

Rating and Price Target Changes

The downgrade reflects a shift in the investment stance on Sabra Health Care REIT. The adjustment in the price target suggests a recalibration of the stock's potential upside based on current market conditions.

Metric Previous New
Rating Buy Neutral
Price Target $24 $19

What specific market conditions or operational factors prompted Citigroup to revise its outlook for Sabra Health Care REIT?

How might this downgrade influence other analysts' ratings and investor sentiment towards the healthcare REIT sector?

What are the potential risks or opportunities for Sabra Health Care REIT in the current economic environment that could affect its stock performance?

like20
dislike

Scotiabank lowers Sabra Health Care REIT target to $19

0 min read     Updated on 18 Jun 2026, 09:07 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Scotiabank analyst Nicholas Yulico maintained Sabra Health Care REIT with a Sector Perform rating and lowered the price target to $19 from $22.

powered bylight_fuzz_icon
43342648

*this image is generated using AI for illustrative purposes only.

Scotiabank analyst Nicholas Yulico maintained Sabra Health Care REIT with a Sector Perform rating while lowering the price target to $19 from $22. The adjustment reflects a revised outlook for the healthcare real estate investment trust.

The rating remains unchanged as Sector Perform, indicating an expectation for the stock to perform in line with the broader sector. The price target reduction suggests a more conservative valuation of the company's near-term potential.

Metric Previous New
Price Target $22 $19
Rating Sector Perform Sector Perform

What specific factors led to the revised outlook for Sabra Health Care REIT's near-term potential?

How might this price target reduction influence investor sentiment towards the healthcare REIT sector?

What are the potential risks or challenges facing Sabra Health Care REIT in the current market environment?

like18
dislike

More News on Sabra Health Care REIT Inc